Press Releases

Investors

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
PASADENA, Calif. --(BUSINESS WIRE)--Jun. 21, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on June 14, 2019 , the Compensation Committee of the Board of Directors approved "inducement" grants to 11 new
View HTML
Toggle Summary Arrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-APOC3
PASADENA, Calif. --(BUSINESS WIRE)--Jun. 21, 2019-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the U.S. Food and Drug Administration ( FDA ) has granted orphan drug designation to ARO-APOC3 for the treatment of familial chylomicronemia syndrome (FCS).
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Present at Upcoming June 2019 Conferences
PASADENA, Calif. --(BUSINESS WIRE)--May 31, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: Jefferies 2019 Global Health Care Conference – New York , June 4-7, 2019 June 6 , 9:30 a.m.
View HTML
Toggle Summary Arrowhead Pharmaceuticals Reports Fiscal 2019 Second Quarter Results
— Conference Call and Webcast Today at 4:30 p.m. EDT PASADENA, Calif. --(BUSINESS WIRE)--May 8, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2019 second quarter ended March 31, 2019 . The company is hosting a conference call at 4:30 p.m.
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Present at Upcoming May 2019 Conferences
PASADENA, Calif. --(BUSINESS WIRE)--May 2, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: Bank of America Merrill Lynch 2019 Health Care Conference – Las Vegas , May 14-16, 2019 May 15 , 8:40 a.m.
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Webcast Fiscal 2019 Second Quarter Results
PASADENA, Calif. --(BUSINESS WIRE)--Apr. 24, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 8, 2019 , at 4:30 p.m. EDT to discuss its financial results for the fiscal 2019 second quarter ended March 31, 2019 .
View HTML
Toggle Summary Arrowhead Begins Triple Combination Cohort in Chronic HBV Patients and Earns $25 Million Milestone Payment from Janssen
PASADENA, Calif. --(BUSINESS WIRE)--Apr. 24, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has begun dosing in a new triple combination cohort (cohort 12) that includes JNJ-3989 (formerly ARO-HBV) and additional undisclosed agents selected by Janssen Pharmaceuticals,
View HTML
Toggle Summary Arrowhead Pharmaceuticals Receives FDA Clearance to Begin Phase 2/3 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
PASADENA, Calif. --(BUSINESS WIRE)--Apr. 15, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has received clearance from the U.S. Food and Drug Administration to proceed with an adaptive Phase 2/3 trial with the potential to serve as a pivotal registrational study of
View HTML
Toggle Summary Arrowhead Presents Clinical Data on JNJ-3989 (ARO-HBV) at The International Liver Congress™
PASADENA, Calif. --(BUSINESS WIRE)--Apr. 12, 2019-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the presentation of clinical data from an ongoing Phase 1/2 study (AROHBV1001) of JNJ-3989 (formerly ARO-HBV), a third-generation subcutaneously administered RNA interference (RNAi)
View HTML
Toggle Summary Arrowhead Preclinical Data Demonstrates RNAi Therapy Prevents and Reverses Alpha-1 Liver Disease at The International Liver Congress™
PASADENA, Calif. --(BUSINESS WIRE)--Apr. 12, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented preclinical data at The International Liver Congress™ 2019 (ILC), the annual meeting of the European Association for the Study of the Liver (EASL), demonstrating that sustained
View HTML